Document Detail


Biodegradable intraprostatic doxorubicin implants.
MedLine Citation:
PMID:  17907765     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Systemic chemotherapy is not effective in the treatment of prostate-confined cancer. We developed biodegradable, doxorubicin-loaded cylinders for intraprostatic implantation and evaluated the feasibility of using regional intraprostatic drug therapy to treat prostate-confined cancer. Cylinders were prepared using poly(lactide-co-glycolide) (PLG) or PLG copolymers. The in vitro and in vivo drug release, intraprostatic pharmacokinetics, and histopathology in dogs implanted with the cylinders were studied. The doxorubicin-loaded cylinders made of PLG polymers of 7.9 to 54 kDa molecular weight (MW) had a diameter of ~800 mum, drug loading of 10% to 30% (wt/wt), and even distribution of crystalline drug throughout the matrix. Burst release varied from 3% to 73%, and 7-day cumulative release from 4% to 90%. Decreasing polymer MW and increasing drug loading were associated with higher initial burst release and overall release rates. The in vivo drug release from cylinders (33-kDa PLG, 30% drug loading) in dog prostates was rapid (approximately 80% in 48 hours). Spatial drug distribution, visualized using confocal fluorescence microscopy, showed high concentrations confined to the lobule containing the implant (referred to as the implanted lobule), with steep concentration gradients over the septa separating the lobules. Concentrations in the implanted lobule were about 8 times higher than concentrations delivered by an intravenous injection. The implants caused necrotic cell death in the implanted lobule, without damage to prostatic nerve bundles or the urethra. These results indicate the feasibility of using biodegradable PLG cylinders as intraprostatic implants to selectively deliver high drug concentrations to prostate tissue.
Authors:
Ronnie Ortiz; Jessie L-S Au; Ze Lu; Yuebo Gan; M Guillaume Wientjes
Related Documents :
1482335 - Evaluation of two epoxy ether compounds for biocompatible potential.
23039395 - A comparative evaluation of dimensional stability of three types of interocclusal recor...
24577855 - Anatomical research on the subacromial interval following implantation of clavicle hook...
7065735 - D-penicillamine-induced enhancement of the delayed hypersensitivity reaction in guinea-...
7674185 - Seating accuracy and fracture strength of vented and nonvented ceramic crowns luted wit...
1501185 - Biocompatibility testing of a silicone maxillofacial prosthetic elastomer: soft tissue ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2007-06-29
Journal Detail:
Title:  The AAPS journal     Volume:  9     ISSN:  1550-7416     ISO Abbreviation:  AAPS J     Publication Date:  2007  
Date Detail:
Created Date:  2007-10-02     Completed Date:  2007-10-25     Revised Date:  2013-06-06    
Medline Journal Info:
Nlm Unique ID:  101223209     Medline TA:  AAPS J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  E241-50     Citation Subset:  IM    
Affiliation:
College of Pharmacy, Ohio State University, Columbus, OH, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Absorbable Implants*
Animals
Antibiotics, Antineoplastic / administration & dosage*,  adverse effects,  pharmacokinetics,  therapeutic use
Dogs
Doxorubicin / administration & dosage*,  adverse effects,  pharmacokinetics,  therapeutic use
Drug Delivery Systems / methods*
Male
Prostate / drug effects*,  metabolism
Prostatic Neoplasms / blood,  drug therapy*,  metabolism
Tissue Distribution
Grant Support
ID/Acronym/Agency:
R01CA74179/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 23214-92-8/Doxorubicin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Varying polymer architecture to deliver drugs.
Next Document:  O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.